BioCentury | Feb 18, 2021
Management Tracks

Day One names York COO, CFO; plus moves at Coherus, Antios, ArsenalBio, Affinia, Artelo and more

...therapy company from Arog Pharmaceuticals Inc., where she was head of drug development. Matteo Levisetti joined immunotherapy play Cue Biopharma Inc....
...Friedreich’s Ataxia Research Alliance. BC Staff Day One Biopharmaceuticals LLC Coherus BioSciences Inc. Antios Therapeutics Inc. ArsenalBio Affinia Therapeutics Artelo Biosciences Inc. jCyte Inc. Cue Biopharma Inc. Westlake...
BioCentury | Nov 9, 2018
Company News

Cue, LG in biologics deal

...KRX:051910). Cue Biopharma Inc. (NASDAQ:CUE), Cambridge, Mass. LG Chem Ltd. (KRX:051910), Seoul, South Korea Business: Cancer Elizabeth S. Eaton CUE-101 Cue Biopharma Inc. LG...
BioCentury | Oct 31, 2018
Distillery Techniques

Imaging; other

...93.9% specificity, compared with 80.8% sensitivity and 87.5% specificity without the model. Next steps by Imagen...
...Oct. 22, 2018 doi:10.1073/pnas.1806905115 CONTACT: Robert Lindsey, Imagen Technologies Inc., New York, N.Y. email: rob@imagen.ai Claire Quang Imagen...
BioCentury | Jun 1, 2018
Clinical News

AI-based diagnostic for wrist fractures gets FDA green light

...FDA has permitted marketing of OsteoDetect, an artificial intelligence-based software product from Imagen Technologies Inc. (New...
...of Clinical Oncology (ASCO) meeting in Chicago, Gottlieb said in a tweet on May 25. Imagen...
BioCentury | May 25, 2018
Company News

AI-based diagnostic for wrist fractures gets FDA green light

...FDA has permitted marketing of OsteoDetect, an artificial intelligence-based software product from Imagen Technologies (New York...
...American Society of Clinical Oncology (ASCO) meeting in Chicago, Gottlieb said in a tweet Friday. Jennie Walters Imagen OsteoDetect...
BioCentury | Apr 25, 2018
Company News

Management tracks: Urovant, Cue

...counsel at Allergan. Ocampo was CFO at Novus Therapeutics Inc. (NASDAQ:NVUS). Cancer and autoimmune company Cue Biopharma Inc....
BioCentury | Jan 5, 2018
Financial News

Autoimmune company Cue raises $66.2 million IPO

...Cancer and autoimmune company Cue Biopharma Inc. (NASDAQ:CUE) raised $66.2 million on Jan. 2 through the sale of...
...million by selling its shares at $6-$8. Cue Biopharma Inc., Cambridge, Mass. Jaime De Leon Albert Einstein College of Medicine Cue Biopharma Inc. Merck...
BioCentury | Jan 2, 2018
Financial News

Cue spikes after pricing $66.2M IPO

...Cancer and autoimmune company Cue Biopharma Inc. (NASDAQ:CUE) climbed $4.13 (55%) to $11.63 in its first day of...
...shares at $6-$8 (see BioCentury Extra, Sept. 22, 2017) . Jaime De Leon Albert Einstein College of Medicine Cue Biopharma Inc. Merck...
BioCentury | Dec 8, 2017
Financial News

Cancer company Cue Biopharma updates IPO plans

...Cancer company Cue Biopharma Inc. (Cambridge, Mass.) amended its proposed IPO on Dec. 5 and now plans to...
...underwritten by MDB Capital Group and Feltl (see BioCentury, Sept. 29 ). Cue Biopharma Inc., Cambridge, Mass. Jennie Walters Cue Biopharma Inc....
BioCentury | Dec 7, 2017
Company News

Management Tracks: Sunesis, Vital

...at the Johnson & Johnson Innovation LLC subsidiary of Johnson & Johnson (NYSE:JNJ). Cancer play Cue Biopharma Inc....
Items per page:
1 - 10 of 30
BioCentury | Feb 18, 2021
Management Tracks

Day One names York COO, CFO; plus moves at Coherus, Antios, ArsenalBio, Affinia, Artelo and more

...therapy company from Arog Pharmaceuticals Inc., where she was head of drug development. Matteo Levisetti joined immunotherapy play Cue Biopharma Inc....
...Friedreich’s Ataxia Research Alliance. BC Staff Day One Biopharmaceuticals LLC Coherus BioSciences Inc. Antios Therapeutics Inc. ArsenalBio Affinia Therapeutics Artelo Biosciences Inc. jCyte Inc. Cue Biopharma Inc. Westlake...
BioCentury | Nov 9, 2018
Company News

Cue, LG in biologics deal

...KRX:051910). Cue Biopharma Inc. (NASDAQ:CUE), Cambridge, Mass. LG Chem Ltd. (KRX:051910), Seoul, South Korea Business: Cancer Elizabeth S. Eaton CUE-101 Cue Biopharma Inc. LG...
BioCentury | Oct 31, 2018
Distillery Techniques

Imaging; other

...93.9% specificity, compared with 80.8% sensitivity and 87.5% specificity without the model. Next steps by Imagen...
...Oct. 22, 2018 doi:10.1073/pnas.1806905115 CONTACT: Robert Lindsey, Imagen Technologies Inc., New York, N.Y. email: rob@imagen.ai Claire Quang Imagen...
BioCentury | Jun 1, 2018
Clinical News

AI-based diagnostic for wrist fractures gets FDA green light

...FDA has permitted marketing of OsteoDetect, an artificial intelligence-based software product from Imagen Technologies Inc. (New...
...of Clinical Oncology (ASCO) meeting in Chicago, Gottlieb said in a tweet on May 25. Imagen...
BioCentury | May 25, 2018
Company News

AI-based diagnostic for wrist fractures gets FDA green light

...FDA has permitted marketing of OsteoDetect, an artificial intelligence-based software product from Imagen Technologies (New York...
...American Society of Clinical Oncology (ASCO) meeting in Chicago, Gottlieb said in a tweet Friday. Jennie Walters Imagen OsteoDetect...
BioCentury | Apr 25, 2018
Company News

Management tracks: Urovant, Cue

...counsel at Allergan. Ocampo was CFO at Novus Therapeutics Inc. (NASDAQ:NVUS). Cancer and autoimmune company Cue Biopharma Inc....
BioCentury | Jan 5, 2018
Financial News

Autoimmune company Cue raises $66.2 million IPO

...Cancer and autoimmune company Cue Biopharma Inc. (NASDAQ:CUE) raised $66.2 million on Jan. 2 through the sale of...
...million by selling its shares at $6-$8. Cue Biopharma Inc., Cambridge, Mass. Jaime De Leon Albert Einstein College of Medicine Cue Biopharma Inc. Merck...
BioCentury | Jan 2, 2018
Financial News

Cue spikes after pricing $66.2M IPO

...Cancer and autoimmune company Cue Biopharma Inc. (NASDAQ:CUE) climbed $4.13 (55%) to $11.63 in its first day of...
...shares at $6-$8 (see BioCentury Extra, Sept. 22, 2017) . Jaime De Leon Albert Einstein College of Medicine Cue Biopharma Inc. Merck...
BioCentury | Dec 8, 2017
Financial News

Cancer company Cue Biopharma updates IPO plans

...Cancer company Cue Biopharma Inc. (Cambridge, Mass.) amended its proposed IPO on Dec. 5 and now plans to...
...underwritten by MDB Capital Group and Feltl (see BioCentury, Sept. 29 ). Cue Biopharma Inc., Cambridge, Mass. Jennie Walters Cue Biopharma Inc....
BioCentury | Dec 7, 2017
Company News

Management Tracks: Sunesis, Vital

...at the Johnson & Johnson Innovation LLC subsidiary of Johnson & Johnson (NYSE:JNJ). Cancer play Cue Biopharma Inc....
Items per page:
1 - 10 of 30